We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-2.24%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
+$368M
Cap. Flow
+$592M
Cap. Flow %
35.11%
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
33
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$82.5M
2
APLT
Applied Therapeutics
APLT
+$64.9M
3
NUVL
Nuvalent
NUVL
+$56M
4
VERA icon
Vera Therapeutics
VERA
+$47.6M
5
CYTK icon
Cytokinetics
CYTK
+$44.1M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$63.9M
2
INSM icon
Insmed
INSM
+$50.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$33.8M
4
JANX icon
Janux Therapeutics
JANX
+$22M
5
EW icon
Edwards Lifesciences
EW
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
1
Jazz Pharmaceuticals
JAZZ
$16.1B
$120M 7.12%
975,000
+75,000
+8% +$8.84M
CYTK icon
2
Cytokinetics
CYTK
$10.8B
$111M 6.55%
2,350,000
+850,000
+57% +$44.1M
MRK icon
3
Merck
MRK
$326B
$79.6M 4.72%
+800,000
New +$82.5M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$71.6M 4.24%
520,000
+270,000
+108% +$35.5M
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.56B
$63.1M 3.74%
1,500,000
+750,000
+100% +$37.2M
INSM icon
6
Insmed
INSM
$22.6B
$62.1M 3.68%
900,000
-700,000
-44% -$50.4M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12B
$56.5M 3.35%
860,000
+460,000
+115% +$30.8M
QURE icon
8
uniQure
QURE
$2.52B
$53.4M 3.17%
3,025,000
-1,725,000
-36% -$14.9M
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$47.6M 2.82%
1,060,000
+340,000
+47% +$17.6M
NUVL
10
DELISTED
Nuvalent
NUVL
$47M 2.78%
+600,000
New +$56M
GPCR icon
11
Structure Therapeutics
GPCR
$3.4B
$46.8M 2.77%
1,725,000
+575,000
+50% +$20.4M
VERA icon
12
Vera Therapeutics
VERA
$2.39B
$45.5M 2.7%
+1,075,000
New +$47.6M
IMTX icon
13
Immatics
IMTX
$1.19B
$44.6M 2.65%
6,275,000
+2,525,000
+67% +$21.7M
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$40.4M 2.4%
4,770,000
+770,000
+19% +$7.97M
GERN icon
15
Geron
GERN
$930M
$38.9M 2.31%
11,000,000
+9,950,000
+948% +$39.7M
ATXS
16
DELISTED
Astria Therapeutics
ATXS
$37.4M 2.22%
4,180,000
+180,000
+5% +$1.91M
ACLX
17
DELISTED
Arcellx
ACLX
$36.4M 2.16%
475,000
-200,000
-30% -$17.3M
SNY icon
18
Sanofi
SNY
$109B
$36.2M 2.14%
750,000
+600,000
+400% +$30.5M
GSK icon
19
GSK
GSK
$108B
$33.8M 2.01%
1,000,000
+700,000
+233% +$25.2M
SVRA icon
20
Savara
SVRA
$1.09B
$33.1M 1.96%
10,775,000
+2,685,000
+33% +$9.36M
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.28B
$31.8M 1.88%
810,000
-15,000
-2% -$620K
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$31.6M 1.87%
+3,350,000
New +$34.8M
AZN icon
23
AstraZeneca
AZN
$267B
$31.1M 1.85%
+237,500
New +$33.3M
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.63B
$30.4M 1.8%
+250,000
New +$30.6M
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.4B
$29.3M 1.74%
95,000
+65,000
+217% +$18.3M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Vestal Point Capital held 93 positions worth $1.69B, up 28% from $1.32B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Vestal Point Capital deployed $592M of net new capital in Q4 2024, opening 24 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 800,000 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $50.4M trimmed.

  • Vestal Point Capital's largest Q4 2024 buy was Merck: 800,000 shares worth $79.6M.
  • Vestal Point Capital added most to Applied Therapeutics in Q4 2024, an estimated $64.9M increase.
  • Vestal Point Capital's biggest Q4 2024 reduction was Insmed, cutting an estimated $50.4M.
  • Vestal Point Capital fully exited Inari Medical, Inc. Common Stock in Q4 2024, selling an estimated $63.9M.
  • Vestal Point Capital's ten largest holdings make up 42% of its $1.69B portfolio in Q4 2024.
  • Vestal Point Capital opened 24 new positions and closed 20 in Q4 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.69B.

Based on Vestal Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.